# A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants

> **NCT03943056** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 64 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** BIIB091
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03943056
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-13
- **Primary completion:** 2020-01-10
- **Final completion:** 2020-01-10
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2021-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03943056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03943056, "A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03943056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*